On June 24, 2020 Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, reported the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $8.00 per share (Press release, Magenta Therapeutics, JUN 24, 2020, View Source [SID1234561451]). Magenta also granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $60.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares in the offering are to be sold by Magenta.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Goldman Sachs & Co. LLC and Cowen are acting as joint bookrunning managers for the offering. The offering is expected to close on or about June 29, 2020, subject to customary closing conditions.

The securities described may be offered pursuant to a shelf registration statement on Form S-3 (File No. 333-233127), including a base prospectus. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the U.S. Securities and Exchange Commission (the "SEC") on June 24, 2020. The final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus relating to these shares may also be obtained from: Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 866-471-2526, facsimile: 212-902-9316, e-mail: [email protected]; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Attn: Prospectus Department, by telephone at (833) 297-2926, or by email at [email protected].

Important Information

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any offer or sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On June 24, 2020 Castle Biosciences, Inc. (Nasdaq: CSTL), reported the pricing of its underwritten public offering of 2,000,000 shares of its common stock at a price to the public of $37.00 per share (Press release, Castle Biosciences, JUN 24, 2020, View Source [SID1234561450]). The gross proceeds to Castle Biosciences from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $74.0 million. In addition, Castle Biosciences has granted the underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock at the offering price, less the underwriting discounts and commissions. The offering is expected to close on June 29, 2020, subject to customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SVB Leerink and Baird are joint book-running managers for the offering and representatives of the underwriters. Canaccord Genuity is a passive book-runner and BTIG is a co-manager for the offering.

Registration statements relating to these securities have been filed with the Securities and Exchange Commission ("SEC") and became effective on June 24, 2020. The offering is being made only by means of a prospectus. A preliminary prospectus related to this offering was filed with the SEC and is available on the SEC’s website located at View Source." target="_blank" title="View Source." rel="nofollow">View Source A final prospectus related to the offering, when available, may be obtained for free by visiting the SEC’s website located at View Source; from SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone: (800) 808-7525, ext. 6218, or by email: [email protected]; or from Robert W. Baird & Co. Incorporated, Attention: Syndicate Department, 777 East Wisconsin Ave., Milwaukee, WI 53202, by telephone: (800) 792-2473, or by email: [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

On June 24, 2020 Onco360, the nation’s largest independent Oncology Pharmacy, reported that it has been selected by Karyopharm to be a specialty pharmacy partner for XPOVIO (selinexor), a new oral treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy (Press release, Onco360, JUN 24, 2020, View Source [SID1234561449]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Onco360 is excited to be selected as a specialty pharmacy provider for XPOVIO patients," said Paul Jardina, President and CEO, Onco360. "The recent approval of XPOVIO unlocks a new treatment option for relapsed or refractory DLBCL patients who have failed previous lines of treatment. As a provider of this key treatment, Onco360 can support the highly specialized needs of relapsed or refractory DLBCL patients and their physicians across the states."

DLBCL is the most common type of non-Hodgkin lymphoma (NHL). According to the National Comprehensive Cancer Network Guidelines for B-Cell Lymphomas, 74,200 patients are diagnosed with NHL annually with a corresponding 19,970 deaths from NHL annually. Approximately 32% of NHL cases are classified as DLBCL. The median age at initial diagnosis with DLBCL is 66 years old. The five-year overall survival for DLBCL is 63.8% when considering all stages of disease.

XPOVIO is manufactured by Karyopharm Therapeutics, a global, commercial-stage, research-based biotechnology company, and was previously approved by the U.S. FDA for the treatment of adult patients with relapsed or refractory multiple myeloma, in combination with dexamethasone, who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. The FDA’s approval of XPOVIO for relapsed/refractory DLBCL is based on the results of the Phase IIb SADAL (NCT02227251) Clinical Trial which demonstrated a 29% overall response rate in patients who failed two to five prior lines of systemic therapy. For full prescribing information, visit XPOVIO.com.

On June 24, 2020 CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, reported that Geert Kersten, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25, 2020 at 12:30 p.m. ET (Press release, Cel-Sci, JUN 24, 2020, View Source [SID1234561448]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the chat will be available at View Source or on the Investor Relations section of CEL-SCI’s website at cel-sci.com/new-investor-information/, where it will be archived for approximately 90 days.

The focus of this Fireside Chat Series is how COVID-19 has made biodefense and pandemic preparedness important again and how preparedness gives rise to potential commercial opportunities. Aside from its almost finished Phase 3 clinical trial in cancer immunotherapy, CEL-SCI also has an ongoing program using another technology that has previously shown good results against pandemic flu and is now being developed against COVID-19.

On June 24, 2020 Grid Therapeutics, LLC, a clinical stage biotechnology company developing a first-in-class, novel, human-derived targeted immunotherapy for solid tumors, reported that the first patient has been dosed in a Phase 1/2 study of GT103 in patients with refractory NSCLC (Press release, Grid Therapeutics, JUN 24, 2020, View Source [SID1234561447]). The study is initially being conducted at the Duke University Medical Center.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Today’s announcement marks the first time a therapeutic antibody derived from single B cells of cancer patients, and the first IgG3 subclass, has advanced to the clinic," said Dr. Edward Patz Jr., M.D., Chief Executive Officer of Grid, and the James and Alice Chen Professor of Radiology, Professor in Pharmacology and Cancer Biology at Duke University School of Medicine. "Initiation of this study is a significant milestone for Grid, as we believe our unique strategy will transform cancer therapy."

The Phase 1 segment of this trial will generate important data about the safety and tolerability of GT103, which targets complement factor H, a protein that protects tumor cells from complement lysis. The Phase 2 segment will be performed in combination with a checkpoint inhibitor, as recent pre-clinical data shows GT103 modulates the adaptive immune response and may potentiate current immune-oncology therapy.

Paolo Paoletti, Grid Board member and Chief Executive Officer of GammaDelta Therapeutics, stated, "This is an exciting and pioneering approach to a highly prevalent and intractable cancer, which currently has a very poor prognosis despite best available treatments."

This trial is also designed to validate Grid’s innovative platform for the rapid development of additional therapeutic antibodies for the treatment of multiple forms of cancer.

About the Study

The Phase 1 open-label, dose-escalation clinical trial of GT103 is designed to assess the safety and tolerability of GT103 as a single agent. The study will enroll subjects with refractory NSCLC. Key objectives in the study include determining the recommended Phase 2 dose, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity. An expansion cohort and combination study with checkpoint inhibitors is planned to rapidly follow. Please refer to www.clinialtrials.gov for additional clinical trial details.